<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05560000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P04049</UniProt_ID>
  <Seq_Length>648</Seq_Length>
  <Molecule_Weight>73052</Molecule_Weight>
  <KEGG_ID>hsa:5894</KEGG_ID>
  <Orthology_ID>K04366</Orthology_ID>
  <EBI_ID>EBI-365996</EBI_ID>
  <Function_Summary>Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00130:C1_1@@PF07714:Pkinase_Tyr@@PF02196:RBD</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>cRaf</Alias>
      <Alias>Proto-oncogene c-RAF</Alias>
      <Alias>Raf-1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Conveys a signal from an upstream receptor or intracellular signal transducer, converting the signal into a form where it can ultimately trigger a change in the state or activity of a cell.</Detail>
      <Keyword>Receptor signaling protein activity</Keyword>
      <Ontology_ID>GO:0005057</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>259</Position>
      <Original>Ser</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>260</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>491</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>263</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>260</Position>
      <Original>Thr</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>335</Position>
      <Original>Gln</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>256</Position>
      <Original>Arg</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>257</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>612</Position>
      <Original>Ser</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>259</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>613</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>486</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>308</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>486</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>491</Position>
      <Original>Thr</Original>
      <Variation>Arg</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Fibroblast growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008543</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of caspase activity.</Detail>
      <Keyword>Negative regulation of caspase activity</Keyword>
      <Ontology_ID>GO:0043154</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of at least three protein kinase activities culminating in the phosphorylation and activation of a MAP kinase. MAPKKK cascades lie downstream of numerous signaling pathways.</Detail>
      <Keyword>MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0000165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the nerve growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Nerve growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048011</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.</Detail>
      <Keyword>Synaptic transmission</Keyword>
      <Ontology_ID>GO:0007268</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-serine.</Detail>
      <Keyword>Positive regulation of peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0033138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.</Detail>
      <Keyword>Negative regulation of protein complex assembly</Keyword>
      <Ontology_ID>GO:0031333</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features.</Detail>
      <Keyword>Regulation of cell differentiation</Keyword>
      <Ontology_ID>GO:0045595</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of Rho protein signal transduction.</Detail>
      <Keyword>Regulation of Rho protein signal transduction</Keyword>
      <Ontology_ID>GO:0035023</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initiation of the activity of the inactive enzyme MAP kinase kinase by phosphorylation by a MAPKKK.</Detail>
      <Keyword>Activation of MAPKK activity</Keyword>
      <Ontology_ID>GO:0000186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a cell population.</Detail>
      <Keyword>Cell proliferation</Keyword>
      <Ontology_ID>GO:0008283</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.</Detail>
      <Keyword>Insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals within the cell that are mediated by a member of the Ras superfamily of proteins switching to a GTP-bound active state.</Detail>
      <Keyword>Ras protein signal transduction</Keyword>
      <Ontology_ID>GO:0007265</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of an epidermal growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Epidermal growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0007173</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the rate or extent of cell proliferation.</Detail>
      <Keyword>Negative regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008285</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of cell motility.</Detail>
      <Keyword>Regulation of cell motility</Keyword>
      <Ontology_ID>GO:2000145</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>612</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>338</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>233</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>43</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>471</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>491</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>268</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>257</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>563</Position>
      <PTM_Type>Symmetric dimethylarginine</PTM_Type>
    </PTM>
    <PTM>
      <Position>621</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>244</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>252</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>642</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>258</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>259</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>497</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>494</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>296</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>294</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>341</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>289</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>340</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>499</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>29</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>339</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>301</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>269</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MEHIQGAWKTISNGFGFKDAVFDGSSCISPTIVQQFGYQRRASDDGKLTDPSKTSNTIRVFLPNKQRTVVNVRNGMSLHDCLMKALKVRGLQPECCAVFRLLHEHKGKKARLDWNTDAASLIGEELQVDFLDHVPLTTHNFARKTFLKLAFCDICQKFLLNGFRCQTCGYKFHEHCSTKVPTMCVDWSNIRQLLLFPNSTIGDSGVPALPSLTMRRMRESVSRMPVSSQHRYSTPHAFTFNTSSPSSEGSLSQRQRSTSTPNVHMVSTTLPVDSRMIEDAIRSHSESASPSALSSSPNNLSPTGWSQPKTPVPAQRERAPVSGTQEKNKIRPRGQRDSSYYWEIEASEVMLSTRIGSGSFGTVYKGKWHGDVAVKILKVVDPTPEQFQAFRNEVAVLRKTRHVNILLFMGYMTKDNLAIVTQWCEGSSLYKHLHVQETKFQMFQLIDIARQTAQGMDYLHAKNIIHRDMKSNNIFLHEGLTVKIGDFGLATVKSRWSGSQQVEQPTGSVLWMAPEVIRMQDNNPFSFQSDVYSYGIVLYELMTGELPYSHINNRDQIIFMVGRGYASPDLSKLYKNCPKAMKRLVADCVKKVKEERPLFPQILSSIELLQHSLPKINRSASEPSLHRAAHTEDINACTLTTSPRLPVF</Protein_Seq>
    <DNA_Seq>AGAATCGGAGAGCCGGTGGCGTCGCAGGTCGGGAGGACGAGCACCGAGTCGAGGGCTCGCTCGTCTGGGCCGCCCGAGAGTCTTAATCGCGGGCGCTTGGGCCGCCATCTTAGATGGCGGGAGTAAGAGGAAAACGATTGTGAGGCGGGAACGGCTTTCTGCTGCCTTTTTTGGGCCCCGAAAAGGGTCAGCTGGCCGGGCTTTGGGGCGCGTGCCCTGAGGCGCGGAGCGCGTTTGCTACGATGCGGGGGCTGCTCGGGGCTCCGTCCCCTGGGCTGGGGACGCGCCGAATGTGACCGCCTCCCGCTCCCTCACCCGCCGCGGGGAGGAGGAGCGGGCGAGAAGCTGCCGCCGAACGACAGGACGTTGGGGCGGCCTGGCTCCCTCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAGATGCCGTGTTTGATGGCTCCAGCTGCATCTCTCCTACAATAGTTCAGCAGTTTGGCTATCAGCGCCGGGCATCAGATGATGGCAAACTCACAGATCCTTCTAAGACAAGCAACACTATCCGTGTTTTCTTGCCGAACAAGCAAAGAACAGTGGTCAATGTGCGAAATGGAATGAGCTTGCATGACTGCCTTATGAAAGCACTCAAGGTGAGGGGCCTGCAACCAGAGTGCTGTGCAGTGTTCAGACTTCTCCACGAACACAAAGGTAAAAAAGCACGCTTAGATTGGAATACTGATGCTGCGTCTTTGATTGGAGAAGAACTTCAAGTAGATTTCCTGGATCATGTTCCCCTCACAACACACAACTTTGCTCGGAAGACGTTCCTGAAGCTTGCCTTCTGTGACATCTGTCAGAAATTCCTGCTCAATGGATTTCGATGTCAGACTTGTGGCTACAAATTTCATGAGCACTGTAGCACCAAAGTACCTACTATGTGTGTGGACTGGAGTAACATCAGACAACTCTTATTGTTTCCAAATTCCACTATTGGTGATAGTGGAGTCCCAGCACTACCTTCTTTGACTATGCGTCGTATGCGAGAGTCTGTTTCCAGGATGCCTGTTAGTTCTCAGCACAGATATTCTACACCTCACGCCTTCACCTTTAACACCTCCAGTCCCTCATCTGAAGGTTCCCTCTCCCAGAGGCAGAGGTCGACATCCACACCTAATGTCCACATGGTCAGCACCACCCTGCCTGTGGACAGCAGGATGATTGAGGATGCAATTCGAAGTCACAGCGAATCAGCCTCACCTTCAGCCCTGTCCAGTAGCCCCAACAATCTGAGCCCAACAGGCTGGTCACAGCCGAAAACCCCCGTGCCAGCACAAAGAGAGCGGGCACCAGTATCTGGGACCCAGGAGAAAAACAAAATTAGGCCTCGTGGACAGAGAGATTCAAGCTATTATTGGGAAATAGAAGCCAGTGAAGTGATGCTGTCCACTCGGATTGGGTCAGGCTCTTTTGGAACTGTTTATAAGGGTAAATGGCACGGAGATGTTGCAGTAAAGATCCTAAAGGTTGTCGACCCAACCCCAGAGCAATTCCAGGCCTTCAGGAATGAGGTGGCTGTTCTGCGCAAAACACGGCATGTGAACATTCTGCTTTTCATGGGGTACATGACAAAGGACAACCTGGCAATTGTGACCCAGTGGTGCGAGGGCAGCAGCCTCTACAAACACCTGCATGTCCAGGAGACCAAGTTTCAGATGTTCCAGCTAATTGACATTGCCCGGCAGACGGCTCAGGGAATGGACTATTTGCATGCAAAGAACATCATCCATAGAGACATGAAATCCAACAATATATTTCTCCATGAAGGCTTAACAGTGAAAATTGGAGATTTTGGTTTGGCAACAGTAAAGTCACGCTGGAGTGGTTCTCAGCAGGTTGAACAACCTACTGGCTCTGTCCTCTGGATGGCCCCAGAGGTGATCCGAATGCAGGATAACAACCCATTCAGTTTCCAGTCGGATGTCTACTCCTATGGCATCGTATTGTATGAACTGATGACGGGGGAGCTTCCTTATTCTCACATCAACAACCGAGATCAGATCATCTTCATGGTGGGCCGAGGATATGCCTCCCCAGATCTTAGTAAGCTATATAAGAACTGCCCCAAAGCAATGAAGAGGCTGGTAGCTGACTGTGTGAAGAAAGTAAAGGAAGAGAGGCCTCTTTTTCCCCAGATCCTGTCTTCCATTGAGCTGCTCCAACACTCTCTACCGAAGATCAACCGGAGCGCTTCCGAGCCATCCTTGCATCGGGCAGCCCACACTGAGGATATCAATGCTTGCACGCTGACCACGTCCCCGAGGCTGCCTGTCTTCTAGTTGACTTTGCACCTGTCTTCAGGCTGCCAGGGGAGGAGGAGAAGCCAGCAGGCACCACTTTTCTGCTCCCTTTCTCCAGAGGCAGAACACATGTTTTCAGAGAAGCTGCTGCTAAGGACCTTCTAGACTGCTCACAGGGCCTTAACTTCATGTTGCCTTCTTTTCTATCCCTTTGGGCCCTGGGAGAAGGAAGCCATTTGCAGTGCTGGTGTGTCCTGCTCCCTCCCCACATTCCCCATGCTCAAGGCCCAGCCTTCTGTAGATGCGCAAGTGGATGTTGATGGTAGTACAAAAAGCAGGGGCCCAGCCCCAGCTGTTGGCTACATGAGTATTTAGAGGAAGTAAGGTAGCAGGCAGTCCAGCCCTGATGTGGAGACACATGGGATTTTGGAAATCAGCTTCTGGAGGAATGCATGTCACAGGCGGGACTTTCTTCAGAGAGTGGTGCAGCGCCAGACATTTTGCACATAAGGCACCAAACAGCCCAGGACTGCCGAGACTCTGGCCGCCCGAAGGAGCCTGCTTTGGTACTATGGAACTTTTCTTAGGGGACACGTCCTCCTTTCACAGCTTCTAAGGTGTCCAGTGCATTGGGATGGTTTTCCAGGCAAGGCACTCGGCCAATCCGCATCTCAGCCCTCTCAGGGAGCAGTCTTCCATCATGCTGAATTTTGTCTTCCAGGAGCTGCCCCTATGGGGCGGGGCCGCAGGGCCAGCCTTGTTTCTCTAACAAACAAACAAACAAACAGCCTTGTTTCTCTAGTCACATCATGTGTATACAAGGAAGCCAGGAATACAGGTTTTCTTGATGATTTGGGTTTTAATTTTGTTTTTATTGCACCTGACAAAATACAGTTATCTGATGGTCCCTCAATTATGTTATTTTAATAAAATAAATTAAATTTAGGTGTAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Mitochondrial outer membrane</CellLocal>
      <Ontology_ID>GO:0005741</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Mitochondrion</CellLocal>
      <Ontology_ID>GO:0005739</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>RAF1</Gene_Name>
    <Gene_Alias>RAF</Gene_Alias>
    <Gene_ID>5894</Gene_ID>
    <Genbank_ACCN>NM_002880</Genbank_ACCN>
    <Protein_ACCN>NP_002871</Protein_ACCN>
    <HGNC_ID>9829</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5894</Gene_URL>
    <UCSC_ID>uc003bxf.4</UCSC_ID>
    <EMBL_ID>ENSG00000132155</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>O43482</Uniprot_ID>
      <Gene_Name>OIP5</Gene_Name>
      <EBI_ID>EBI-536879</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-536879</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P01112</Uniprot_ID>
      <Gene_Name>HRAS</Gene_Name>
      <EBI_ID>EBI-350145</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-350145</PPI_EBI_URL>
      <Experiment_Number>8</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P01116-2</Uniprot_ID>
      <Gene_Name>KRAS</Gene_Name>
      <EBI_ID>EBI-367427</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-367427</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13177</Uniprot_ID>
      <Gene_Name>PAK2</Gene_Name>
      <EBI_ID>EBI-1045887</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-1045887</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P15056</Uniprot_ID>
      <Gene_Name>BRAF</Gene_Name>
      <EBI_ID>EBI-365980</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-365980</PPI_EBI_URL>
      <Experiment_Number>30</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04049</Uniprot_ID>
      <Gene_Name>RAF1</Gene_Name>
      <EBI_ID>EBI-365996</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-365996</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49368</Uniprot_ID>
      <Gene_Name>CCT3</Gene_Name>
      <EBI_ID>EBI-356673</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-356673</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q3ZCQ8</Uniprot_ID>
      <Gene_Name>TIMM50</Gene_Name>
      <EBI_ID>EBI-355175</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-355175</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q04917</Uniprot_ID>
      <Gene_Name>YWHAH</Gene_Name>
      <EBI_ID>EBI-306940</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-306940</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P30304</Uniprot_ID>
      <Gene_Name>CDC25A</Gene_Name>
      <EBI_ID>EBI-747671</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-747671</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P53805-2</Uniprot_ID>
      <Gene_Name>RCAN1</Gene_Name>
      <EBI_ID>EBI-1541912</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-1541912</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P31946</Uniprot_ID>
      <Gene_Name>YWHAB</Gene_Name>
      <EBI_ID>EBI-359815</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-359815</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P06400</Uniprot_ID>
      <Gene_Name>RB1</Gene_Name>
      <EBI_ID>EBI-491274</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-491274</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P63104</Uniprot_ID>
      <Gene_Name>YWHAZ</Gene_Name>
      <EBI_ID>EBI-347088</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-347088</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P14618</Uniprot_ID>
      <Gene_Name>PKM2</Gene_Name>
      <EBI_ID>EBI-353408</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-353408</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P31327</Uniprot_ID>
      <Gene_Name>CPS1</Gene_Name>
      <EBI_ID>EBI-536811</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-536811</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P11021</Uniprot_ID>
      <Gene_Name>HSPA5</Gene_Name>
      <EBI_ID>EBI-354921</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-354921</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P62834</Uniprot_ID>
      <Gene_Name>RAP1A</Gene_Name>
      <EBI_ID>EBI-491414</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-491414</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P08238</Uniprot_ID>
      <Gene_Name>HSP90AB1</Gene_Name>
      <EBI_ID>EBI-352572</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-352572</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q02750</Uniprot_ID>
      <Gene_Name>MAP2K1</Gene_Name>
      <EBI_ID>EBI-492564</EBI_ID>
      <PPI_EBI_URL>EBI-365996,EBI-492564</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Leopard Syndrome 1</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>LPR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leopard_syndrome_1?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Murray Valley Encephalitis</Disease_Name>
      <Disease_Detail>Murray Valley Encephalitis</Disease_Detail>
      <Disease_DB>MRR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/murray_valley_encephalitis?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dengue Disease</Disease_Name>
      <Disease_Detail>Dengue Disease</Disease_Detail>
      <Disease_DB>DNG003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dengue_disease?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leopard Syndrome 2</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>LPR011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leopard_syndrome_2?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leopard Syndrome</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>LPR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leopard_syndrome?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiomyopathy, Dilated, 1nn</Disease_Name>
      <Disease_Detail>Cardiomyopathy</Disease_Detail>
      <Disease_DB>CRD173</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiomyopathy_dilated_1nn?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Noonan Syndrome</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>NNN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/noonan_syndrome?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Noonan Syndrome 1</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>NNN008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/noonan_syndrome_1?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pilocytic Astrocytoma</Disease_Name>
      <Disease_Detail>Pilocytic Astrocytoma</Disease_Detail>
      <Disease_DB>PLC011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pilocytic_astrocytoma?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Noonan Syndrome 5</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>NNN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/noonan_syndrome_5?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiofaciocutaneous Syndrome</Disease_Name>
      <Disease_Detail>Cardiofaciocutaneous Syndrome</Disease_Detail>
      <Disease_DB>CRD013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiofaciocutaneous_syndrome?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Raf1-Related Leopard Syndrome</Disease_Name>
      <Disease_Detail>Leopard Syndrome</Disease_Detail>
      <Disease_DB>RF1001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/raf1_related_leopard_syndrome?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Raf1-Related Noonan Syndrome</Disease_Name>
      <Disease_Detail>Noonan Syndrome</Disease_Detail>
      <Disease_DB>RF1002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/raf1_related_noonan_syndrome?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cardiomyopathy, Dilated, 1ii</Disease_Name>
      <Disease_Detail>Cardiomyopathy</Disease_Detail>
      <Disease_DB>CRD162</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cardiomyopathy_dilated_1ii?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Encephalitis</Disease_Name>
      <Disease_Detail>Encephalitis</Disease_Detail>
      <Disease_DB>ENC004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/encephalitis?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pulmonic Stenosis</Disease_Name>
      <Disease_Detail>Pulmonic Stenosis</Disease_Detail>
      <Disease_DB>PLM070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pulmonic_stenosis?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>West Nile Fever</Disease_Name>
      <Disease_Detail>West Nile Fever</Disease_Detail>
      <Disease_DB>WST003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/west_nile_fever?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>St. Louis Encephalitis</Disease_Name>
      <Disease_Detail>St. Louis Encephalitis</Disease_Detail>
      <Disease_DB>STL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/st_louis_encephalitis?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lung Adenoma</Disease_Name>
      <Disease_Detail>Lung Cancer</Disease_Detail>
      <Disease_DB>LNG030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lung_adenoma?search=RAF1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kyasanur Forest Disease</Disease_Name>
      <Disease_Detail>Kyasanur Forest Disease</Disease_Detail>
      <Disease_DB>KYS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kyasanur_forest_disease?search=RAF1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>HUMAN RAP1A, RESIDUES 1-167, DOUBLE MUTANT (E30D,K31E) COMPLEXED WITH GPPNHP AND THE RAS-BINDING-DOMAIN OF HUMAN C-RAF1, RESIDUES 51-131</PDB_Title>
      <PDB_ID>1GUA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GUA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Ras/Rap effector specificity determined by charge reversal.</PubMed_Title>
      <Author>Nassar, N., et al.</Author>
      <Journal>Nat.Struct.Biol.(1996)3:723-729</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8756332?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR SOLUTION STRUCTURE OF THE RAS-BINDING DOMAIN OF C-RAF-1</PDB_Title>
      <PDB_ID>1RFA</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RFA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface.</PubMed_Title>
      <Author>Emerson, S.D., et al.</Author>
      <Journal>Biochemistry(1995)34:6911-6918</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7766599?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex of Ras-GDP with RafRBD(A85K)</PDB_Title>
      <PDB_ID>3KUD</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KUD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf.</PubMed_Title>
      <Author>Filchtinski, D., et al.</Author>
      <Journal>J.Mol.Biol.(2010)399:422-435</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20361980?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer)</PDB_Title>
      <PDB_ID>3IQU</PDB_ID>
      <Resolution>1.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IQU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired binding of 14-3-3 to C-RAF in Noonan Syndrome implies new approaches in diseases with increased Ras signaling.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (10mer)</PDB_Title>
      <PDB_ID>3IQJ</PDB_ID>
      <Resolution>1.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IQJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired binding of 14-3-3 to C-RAF in Noonan Syndrome implies new approaches in diseases with increased Ras signaling.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Complex of Rap1A(E30D/K31E)GDP with RafRBD(A85K/N71R)</PDB_Title>
      <PDB_ID>3KUC</PDB_ID>
      <Resolution>1.92</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KUC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf.</PubMed_Title>
      <Author>Filchtinski, D., et al.</Author>
      <Journal>J.Mol.Biol.(2010)399:422-435</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20361980?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of c-raf (raf-1)</PDB_Title>
      <PDB_ID>3OMV</PDB_ID>
      <Resolution>4.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OMV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.</PubMed_Title>
      <Author>Hatzivassiliou, G., et al.</Author>
      <Journal>Nature(2010)464:431-435</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20130576?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF RAP.GMPPNP IN COMPLEX WITH THE RAS-BINDING-DOMAIN OF C-RAF1 KINASE (RAFRBD).</PDB_Title>
      <PDB_ID>1C1Y</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1C1Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue.</PubMed_Title>
      <Author>Nassar, N., et al.</Author>
      <Journal>Nature(1995)375:554-560</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7791872?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome</PDB_Title>
      <PDB_ID>3CU8</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CU8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusicoccin</PDB_Title>
      <PDB_ID>3IQV</PDB_ID>
      <Resolution>1.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IQV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired binding of 14-3-3 to C-RAF in Noonan Syndrome implies new approaches in diseases with increased Ras signaling.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>RAF-1 CYSTEINE RICH DOMAIN, NMR, 27 STRUCTURES</PDB_Title>
      <PDB_ID>1FAQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FAQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site.</PubMed_Title>
      <Author>Mott, H.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1996)93:8312-8317</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8710867?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome</PDB_Title>
      <PDB_ID>3NKX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NKX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired binding of 14-3-3 to C-RAF in Noonan Syndrome implies new approaches in diseases with increased Ras signaling</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of 14-3-3 isoform sigma in complex with a C-Raf1 peptide and a stabilizing small molecule fragment</PDB_Title>
      <PDB_ID>3O8I</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O8I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling</PubMed_Title>
      <Author>Molzan, M., et al.</Author>
      <Journal>Mol.Cell.Biol.(2010)30:4698-4711</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20679480?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RAF-1 CYSTEINE RICH DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE</PDB_Title>
      <PDB_ID>1FAR</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FAR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site.</PubMed_Title>
      <Author>Mott, H.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1996)93:8312-8317</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8710867?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04662</Pathway_ID>
      <Pathway_Title>B cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04010</Pathway_ID>
      <Pathway_Title>MAPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05231</Pathway_ID>
      <Pathway_Title>Choline metabolism in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04014</Pathway_ID>
      <Pathway_Title>Ras signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04664</Pathway_ID>
      <Pathway_Title>Fc epsilon RI signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04024</Pathway_ID>
      <Pathway_Title>cAMP signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04916</Pathway_ID>
      <Pathway_Title>Melanogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04014</Pathway_ID>
      <Pathway_Title>Ras signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04915</Pathway_ID>
      <Pathway_Title>Estrogen signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05164</Pathway_ID>
      <Pathway_Title>Influenza A</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04022</Pathway_ID>
      <Pathway_Title>cGMP-PKG signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04915</Pathway_ID>
      <Pathway_Title>Estrogen signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04015</Pathway_ID>
      <Pathway_Title>Rap1 signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04921</Pathway_ID>
      <Pathway_Title>Oxytocin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05161</Pathway_ID>
      <Pathway_Title>Hepatitis B</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04912</Pathway_ID>
      <Pathway_Title>GnRH signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04660</Pathway_ID>
      <Pathway_Title>T cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04550</Pathway_ID>
      <Pathway_Title>Signaling pathways regulating pluripotency of stem cells</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05230</Pathway_ID>
      <Pathway_Title>Central carbon metabolism in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04666</Pathway_ID>
      <Pathway_Title>Fc gamma R-mediated phagocytosis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04071</Pathway_ID>
      <Pathway_Title>Sphingolipid signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04370</Pathway_ID>
      <Pathway_Title>VEGF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04540</Pathway_ID>
      <Pathway_Title>Gap junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.da.b.f.b.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1c1y</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>